- How health plans profit—and patients lose—from insulin
- A fantastic new analysis of the gross-to-net bubble
- CVS acknowledges how its PBM profits from 340B
- Reconsidering Amazon
Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more.